IFITM4P

Across TCGA pan-cancer cohorts, IFITM4P RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of IFITM4P’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where IFITM4P RNA is more highly expressed in tumor relative to normal tissue. In most cancer types IFITM4P is over-expressed in tumor, although a few such as LUSC and UCEC show the opposite, repressed pattern.

KIRC, LUSC, and UCEC are the cancer types where IFITM4P tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in IFITM4P RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.794	<.001	12	view →
LUSC	Female	All	−0.803	<.001	7	view →
UCEC	All	All	−0.646	<.001	6	view →
LUAD	All	II,III,IV	−0.591	.003	5	view →
LIHC	Male	All	+0.474	.018	4	view →
BRCA	Female	All	−0.277	<.001	4	view →
KICH	Female	II,III,IV	−0.505	.001	2	view →
CHOL	All	All	+0.664	.022	1	view →
BLCA	All	IV	−0.578	.042	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

IFITM4P–KIRC

Open the KIRC breakdown →